Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Posts 11-Percent Rise in Q2 Profit; Reiterates Q3 Closing for ParAllele Acquisition

NEW YORK, July 21 (GenomeWeb News) - Affymetrix today reported a 5 percent year-over-year increase in revenues and an 11 percent increase in net income for the second quarter of 2005.


Total revenue rose to $84.1 million from $79.8 million in the second quarter of 2004. Of the company's total revenues, $1.9 million was attributed to the sale of products to Perlegen Sciences in the current quarter, compared to $1.4 million in sales to Perlegen in the year-ago period.


Affymetrix reported an increase in net income to $7.8 million, or $.12 per diluted share, from $7.0 million, or $.11 per diluted share, in the prior-year period.


The company did not meet analyst earnings estimates of $.17 per share for the quarter, however.


Affymetrix increased quarterly R&D spending to $20.8 million from $17.8 million in the second quarter of 2004.


The company had cash and cash equivalents of $27 million on hand as of June 30.


Affymetrix reiterated its plans to close its acquisition of ParAllele in the third quarter. As a result, the company expects to incur merger-related charges for in-process R&D of $15 million and operational charges of $7 million in the third quarter.


For the third quarter, Affymetrix has forecast total revenue of $95 million and a net loss per share of $.06 - below analyst estimates of net income of net income of $.29 per share.


Affymetrix reiterated its previous guidance of $405 million in total revenues for the full year.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.